The prospective multicohort phase 2 DEBBRAH trial enrolled a total of seven patients in cohort 5 specifically designed to assess T-DXd in patients with previously untreated pathologically confirmed LMD of HER2-positive and HER2-low breast cancer. This evidence concerns the gene ERBB2 and breast carcinoma.